Erasca Inc ERAS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
-
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
-
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
-
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit
-
Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS
-
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
-
Erasca 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc. - ERAS
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
Trading Information
- Previous Close Price
- $17.86
- Day Range
- $17.30–18.47
- 52-Week Range
- $1.33–24.28
- Bid/Ask
- $17.60 / $18.30
- Shares Outstanding
- 349.76M
- Market Cap
- $6.43B
- Volume/Avg
- 2M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 103
- Website
- https://www.erasca.com
Valuation
|
Metric
|
ERAS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 15.88 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ERAS
|
|---|---|
Quick Ratio | 8.01 |
Current Ratio | 8.29 |
Interest Coverage | — |
Quick Ratio
ERAS
Profitability
|
Metric
|
ERAS
|
|---|---|
Return on Assets (Normalized) | −24.41% |
Return on Equity (Normalized) | −29.26% |
Return on Invested Capital (Normalized) | −29.70% |
Return on Assets
ERAS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|L%$F$# | LOCK|ttBV | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G<^@&r | LOCK|#FzM | $83B | |||
| argenx SE ADR
ARGX
| LOCK|V@!!p#k | LOCK|nPP | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|tKPJv&n | LOCK|<@@z | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|QLX<!< | LOCK|<Q! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ys%GPw | LOCK|T#hM | $31B | |||
| Moderna Inc
MRNA
| LOCK|#gnB&z | LOCK|N!@ | $25B | |||
| Incyte Corp
INCY
| LOCK|#&#%$! | LOCK|<? | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|CpHl%s | LOCK|?> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@Bh&zR | LOCK|?< | $16B |
United States